Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06237036
Other study ID # LEGIT_COVIDX_EVCDAO_2022
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 3, 2022
Est. completion date October 23, 2023

Study information

Verified date February 2024
Source AI Labs Group S.L
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational prospective and analytical study is to evaluate the effectiveness of the device developed by Legit.Health in remotely monitoring the severity of chronic dermatologic pathologies. Secondly, to assess patient satisfaction with the device for remote monitoring. All this in patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón. The study proceeded as follows: Patient Selection and Recruitment Visit The recruitment period spanned six months, during which investigators identified eligible patients. The Principal Investigator (PI) or designated collaborating investigators explained the study details to potential participants using the Patient Information Sheet. Patients had the opportunity to seek clarification on any aspects of the study. If a patient chose to participate, they provided informed consent and received a study code. Data collection commenced post-consent. During this initial visit, patients used the device under the supervision of the research team to complete questionnaires and capture photographs associated with their pathology. Subsequently, the patient autonomously and remotely continued the data collection process at home, as detailed in the following section. The device was provided at no cost to patients and the research team for the study's duration. Procedures Performed by the Patient at Home Completion of Questionnaires Patients independently reported on their condition from home, following instructions provided by the research team and the "Patient Information Guide" integrated into Legit.Health, in conjunction with photograph submissions. Every two months, patients completed the "Patient Satisfaction Questionnaire" addressing general user experience aspects. Additionally, they completed the System Usability Scale (SUS) Questionnaire at the same frequency Image capture Patients simultaneously took photographs of the affected areas while completing questionnaires through the app. These photographs were captured using the patient's smartphone from their homes in an autonomous manner. The frequency of photograph submission was determined by the consulting specialist. No specialized camera equipment was required; patients used the camera available on their smartphones. Patients then transmitted these photographs to the research team through a web app Both patients and members of the medical team possessed access credentials. The manufacturer did not have access to patient accounts or information. Data transfer and photograph storage adhered to the European Regulation 2016/679 of 27 April on the protection of natural persons with regard to the processing of personal data and the free movement of such data, as well as the Organic Law 3/2018 of 5 December on the Protection of Personal Data and guarantee of digital rights.


Description:

Introduction This clinical investigation marks a pivotal stage in the development of the Legit.Health software medical device, designed to enhance dermatological diagnostics using advanced machine vision and deep learning. The study focuses on evaluating the device's effectiveness in remotely monitoring chronic dermatologic conditions and assessing patient satisfaction. With a diverse cohort of 160 patients, rigorous ethical standards, and adherence to regulatory guidelines, this research holds significant potential in revolutionizing dermatological diagnostics. Objectives Primary objective The primary aim of this study is to ascertain the validity of the device, leveraging artificial intelligence and developed by AI Labs Group S.L., in objectively and reliably tracking the progression of chronic dermatological conditions. This validation is deemed successful if the tool achieves a score of 8 or higher in the Clinical Utility Questionnaire (CUS). Secondary objectives In addition to the primary objective, secondary objectives encompass: Confirming that the utilization of the device elicits a high level of patient satisfaction, particularly in its remote application. Demonstrating that the implementation of the device leads to a reduction in face-to-face consultations, thereby optimizing healthcare resources and patient convenience. Validating the device's ability to consistently generate reliable condition monitoring, thereby establishing its trustworthiness as a monitoring system. Population The study encompasses patients diagnosed with any of the specified chronic dermatological conditions that meet the inclusion criteria. These patients are attended at the Dermatology Department of the Hospital Universitario de Torrejón. Design and Methods Design The study proceeded as follows: 1. Patient Selection and Recruitment Visit The recruitment period spanned six months, during which investigators identified eligible patients. The Principal Investigator (PI) or designated collaborating investigators explained the study details to potential participants using the Patient Information Sheet. Patients had the opportunity to seek clarification on any aspects of the study. If a patient chose to participate, they provided informed consent and received a study code. Data collection commenced post-consent. During this initial visit, patients used the device under the supervision of the research team to complete questionnaires and capture photographs associated with their pathology. Subsequently, the patient autonomously and remotely continued the data collection process at home, as detailed in the following section. The device was provided at no cost to patients and the research team for the study's duration. 2. Procedures Performed by the Patient at Home 2.1. Completion of Questionnaires Patients independently reported on their condition from home, following instructions provided by the research team and the "Patient Information Guide" (Appendix IV of the protocol) distributed during the screening visit. At regular intervals, patients documented the status of their pathology using questionnaires and the Dermatology Life Quality Index (DLQI) (Appendix V of the protocol), integrated into Legit.Health, in conjunction with photograph submissions. Every two months, patients completed the "Patient Satisfaction Questionnaire" (Appendix II of the protocol), addressing general user experience aspects. Additionally, they completed the System Usability Scale (SUS) Questionnaire (Appendix III of the protocol) at the same frequency. 2.2. Image Capture Patients simultaneously took photographs of the affected areas while completing questionnaires through the app. These photographs were captured using the patient's smartphone from their homes in an autonomous manner. The frequency of photograph submission was determined by the consulting specialist. No specialized camera equipment was required; patients used the camera available on their smartphones. Patients then transmitted these photographs to the research team through a web app (Appendix VII of the protocol). Both patients and members of the medical team possessed access credentials. The manufacturer did not have access to patient accounts or information. Data transfer and photograph storage adhered to the European Regulation 2016/679 of 27 April on the protection of natural persons with regard to the processing of personal data and the free movement of such data, as well as the Organic Law 3/2018 of 5 December on the Protection of Personal Data and guarantee of digital rights. Number of Subjects A total of 160 patients were recruited in this study. Initiation Date March 03rd, 2022 Completion Date October 23rd, 2023 Duration The study spanned a total duration of 19 months, encompassing the time needed for tasks such as database closure and editing, data analysis, and the preparation of the final study report after the recruitment of the last subject. Methods The study employed a prospective observational analytical design to evaluate the effectiveness of the device in remotely monitoring chronic dermatologic pathologies. The research encompassed a diverse cohort of 160 patients with various dermatological conditions. Data collection involved questionnaires, photograph analysis, and patient satisfaction surveys. The study adhered to strict ethical guidelines, ensuring patient confidentiality and compliance with international standards. Patients were provided with detailed information and informed consent. The study's robust methodology aimed to assess the clinical utility and usability of the device.


Recruitment information / eligibility

Status Completed
Enrollment 160
Est. completion date October 23, 2023
Est. primary completion date October 23, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients who have provided their informed consent for participation in the study. - Patients who demonstrate proficiency in both written and spoken Spanish or English. - Patients who possess a smartphone, defined as a phone equipped with internet access and an integrated camera, regardless of make, model, or technical specifications. Exclusion Criteria: - Patients who, as determined by the investigator, did not adhere to the study procedures. - Patients who were already utilizing the tool under investigation prior to the commencement of the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Spain Torrejón University Hospital Torrejón de Ardoz Madrid

Sponsors (2)

Lead Sponsor Collaborator
AI Labs Group S.L University Hospital of Torrejon

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Malignancy Malignancy of the lesion detected by the tool through study completion, an average of 1 year
Primary Utility Utility of the application referred by the clinicians At the end of the study, up to 1 month
Secondary Sex and age Sex and age of patients through study completion, an average of 1 year
Secondary Diagnosis Clinical data: diagnosis, date of diagnosis, medication the patient is taking. through study completion, an average of 1 year
Secondary Quality of life noticed by patients Quality of life: score of the Dermatology Life Quality Index (DLQI). The questionnaire consists of 10 questions with four alternative answers: "not at all", "a little", "a lot", or "very much" with corresponding scores of 0, 1, 2, and 3, respectively. The response "not relevant" is scored as "0". The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the greater the impairment in quality of life. The DLQI can also be expressed as a percentage of the maximum possible score of 30. through study completion, an average of 1 year
Secondary Satisfaction of patients Degree of patient satisfaction using the patient satisfaction questionnaire At the time of recruitment of the last patient in the study, up to 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT05038982 - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin Phase 2
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Recruiting NCT05102396 - Topical Oxybutynin for Treatment of Hyperidrosis: Local or Systemic Effect? Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Completed NCT00772447 - China Registration Study in Patients With Skin Infections Phase 3
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Active, not recruiting NCT04971200 - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo Early Phase 1
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Recruiting NCT04138342 - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer Phase 1
Recruiting NCT06061471 - To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis Phase 2
Terminated NCT04775316 - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Recruiting NCT05765461 - Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
Withdrawn NCT04593914 - A Novel Skin Barrier Protectant for Acute Radiodermatitis N/A
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT06092866 - Digital Versus Telephone Symptom Assessment and Triage in Primary Care N/A
Recruiting NCT04901325 - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) Phase 2
Recruiting NCT01917279 - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC Phase 3
Completed NCT01975038 - Adaption of the Skin Sun Sensitivity Scale N/A
Recruiting NCT01427400 - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction Phase 4